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Abstract.  The platelet and extracellular matrix glyco- 
protein thrombospondin interacts with various types of 
cells as both a positive and negative modulator of cell 
adhesion,  motility, and proliferation.  These effects may 
be mediated by binding of thrombospondin to cell sur- 
face receptors or indirectly by binding to other ex- 
tracellular matrix components.  The role of peptide se- 
quences from the type I repeats of thrombospondin in 
its interaction with fibronectin were investigated. 
Fibronectin bound specifically to the peptide Gly-Gly- 
Trp-Ser-His-Trp from the second type I repeat of 
thrombospondin but not to the corresponding peptides 
from the first or third repeats or flanking sequences 
from the second repeat.  The two Trp residues and the 
His residue were essential for binding,  and the two 
Gly residues enhanced the affinity of binding.  Binding 
of the peptide and intact thrombospondin to fibronec- 
tin were inhibited by the gelatin-binding  domain of 
fibronectin.  The peptide specifically inhibited binding 
of fibronectin to gelatin or type I collagen and in- 
hibited fibronectin-mediated adhesion of breast carci- 
noma and melanoma cells to gelatin or type I collagen 
substrates but not direct adhesion of the cells to 
fibronectin, which was inhibited by the peptide Gly- 
Arg-Gly-Asp-Ser. Thus, the fibronectin-binding throm- 
bospondin peptide Gly-Gly-Trp-Ser-His-Trp is a  selec- 
tive inhibitor of fibronectin-mediated interactions of 
cells with collagen in the extracellular matrix. 
C 
ELL-MATRIX interactions  are  important  regulators 
of cellular differentiation during development and of 
several pathological  processes including hemostasis, 
wound repair, tumorigenesis,  and tumor metastasis. Throm- 
bospondin is an extracellular  matrix glycoprotein, derived 
from platelet or-granules and secreted by many cell types in 
vitro,  that  may  play  a  role  in  each  of these  processes 
(reviewed in Frazier,  1991; Mosher,  1990).  The biological 
responses of cells to thrombospondin are complex. Throm- 
bospondin can either promote or inhibit adhesion (Roberts 
et al.,  1987; Lahav, 1988),  promote cell migration  but in- 
hibit migration  of the same cells to other attractants  (Tara- 
boletti et al.,  1987, 1990),  and promote growth of smooth 
muscle cells (Majack et al.,  1988) but inhibit growth of en- 
dothelial  cells  (Taraboletti  et al.,  1990).  These opposing 
effects on cell behavior may be mediated directly by binding 
of  thrombospondin  to  specific  cell  surface  receptors 
(reviewed in Frazier,  1991), which are presumed to trans- 
duce information  to the cell. Alternatively,  thrombospendin 
may influence  cell behavior indirectly  by binding  to other 
matrix components, including  collagens,  fibronectin,  lami- 
nin,  proteoglycans,  and  some proteases,  thereby altering 
their biological properties. 
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Several of the ligand binding specificities of thrombospon- 
din have been localized  to a 70-kD protease-resistant core 
fragment of this protein, which contains  the type I repeats 
of thrombospondin-1  (Lawler and Hynes,  1986).  This do- 
main mediates interaction of thrombospondin with fibronec- 
tin,  laminin,  collagens,  and fibrinogen.  This  fragment or 
synthetic peptides,  derived from its sequence or related se- 
quences  from  the  homologous malarial  circumsporozoite 
protein,  are  adhesive  for  lymphoid  and  melanoma  ceils 
(Prater  et al.,  1991; Rich et al.,  1990;  Tuszynski  et al., 
1992).  The  peptides  CSVTCG  and  CSTSCG  from  the 
thrombospondin type I repeats  inhibit  metastasis of mela- 
noma cells in a murine lung colonization  assay (Tuszynski 
et al.,  1992). A 70-kD proteolytic fragment of endothelial 
thrombospondin that contains the type I repeats binds with 
high affinity to endothelial  cells (Dardik and Lahav, 1991). 
Two classes of  biologically active peptides have been derived 
from the 70-kD core region of thrombospondin, containing 
the consensus sequences Val-Thr-Cys-Gly or Trp-Ser-Xaa- 
Trp-Ser.  The former sequence promotes cell adhesion and 
may mediate interactions  of thrombospondin with sulfated 
glycoconjugates  and CD36 (Prater et al., 1991; Asch et al., 
1992).  The  latter  sequence binds  specifically  to  sulfated 
glycoconjugates and promotes cell adhesion and chemotaxis 
(Guo et al., 1992a,b).  The latter sequence is also conserved 
in  members of the cytokine receptor  (Bazan,  1990)  and 
transforming  growth factor fl superfamilies  (Wharton et al., 
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two  of  the  cytokine  receptors  (Miyazaki  et  al.,  1991; 
Yoshimura  et al.,  1992). 
Although most interactions of cells or proteins with pep- 
tides  containing  the  consensus  sequence  Trp-Ser-Xaa-Trp 
are  mediated  by  sulfated  glycoconjugates  (Guo  et  al., 
1992c),  when used as a control protein, human  plasma fi- 
bronectin was  found to bind unexpectedly  avidly  to a  17 
amino acid peptide from the second type I repeat of throm- 
bospondin, KRFKQDGGWSHWSPWSS. We have identified 
a hexapeptide within this sequence that accounts for this in- 
teraction and demonstrate that this peptide interacts primar- 
ily with the gelatin-binding domain of fibronectin. Further- 
more, the peptide is a potent inhibitor of fibronectin binding 
to  gelatin  and  of fibronectin-mediated  cell  adhesion  to  a 
gelatin or collagen matrix. 
Materials and Methods 
Materials 
Human platelet thrombospondin was purified according to the previously 
described method (Roberts et al., 1985).  Fibronectin was isolated from the 
platelet-depleted plasma as described (Akiyama and Yamada,  1985).  Pro- 
teolytic fragments of fibronectin were obtained from Telios Pharmaceuti- 
cals, Inc.  (San Diego,  CA). Recombinant fragments of fibronectin were 
provided by BioTechnology General, Ltd.  (Rehovot, Israel). Gelatin was 
from ICN Biomedicals, Inc. (Costa Mesa, CA), and type I collagen was 
from Collaborative Research, Inc. (Bedford, MA). Other control proteins 
were obtained from Sigma Chemical Co. (St. Louis, MO). Thrombospon- 
din, goat anti-mouse IgG, and fibronectin were iodinated using Iodogen 
(Pierce Chemical Co., Rockford, IL) as previously described (Roberts et 
al.,  1985). 
Peptides were synthesized that corresponded to sequences of human 
thrombospondin-1 deduced from a cDNA sequence for THBS1 (Lawler and 
Hynes, 1986). The peptides used in this study were synthesized on a peptide 
synthesizer (model 9600, Biosearch, San Rafael, CA) using standard Mer- 
rifield solid phase synthesis protocols and t-Boc chemistry. Sequences of 
the peptides used in these studies are presented in Tables I and II. Peptides 
were analyzed and, for some experiments, further purified by reverse-phase 
HPLC using a C18 column. Three independent syntheses of peptide 300 
(GGWSHW) were used in the experiments and had identical activities in 
inhibition assays but differed in their activities for direct binding when im- 
mobilized. Two were analyzed by californium desorption time of  flight mass 
spectroscopy and gave the expected molecular ion at m/z = 729.8. The prep- 
aration with higher activity for direct binding gave a minor ion at m/z = 
785.9, suggesting partial modification with t-butyl. Identities of some of the 
longer peptides, including peptide 246,  were verified by complete amino 
acid sequence analysis. Peptide solutions were neutralized by addition of 
dilute NaOH and stored in solution at  -20°C. 
Ligand Binding Assays 
Direct binding of fibronectin and other proteins to immobilized peptides 
were determined as previously described (Guo et al., 1992a,b). Baldly, the 
peptides were adsorbed on polyvinyl chloride microtiter wells. Saturation 
densities and adsorption capacities for many of the peptides used in these 
experiments have been previously reported (Guo et al., 1992b).  Adsorption 
of the active peptide GGWSHW to plastic was determined after labeling by 
reductive methylation using NaB3I-I4 (Dupont-New England Nuclear, Bos- 
ton, MA) to a  specific activity of 0.69 #Ci/#g.  The peptide adsorbed to 
polyvinyl chloride microtiter plate wells with an adsorption constant of 10 
#M and a capacity of 445 pmol/weU. 
The unbound peptides were removed by washing, and the wells were in- 
cubated for 0.5 h in Tris-BSA (50 mM Tris HCI, pH 7.8, 110 mM NaC1, 
1% BSA (fatty acid and globulin-free, Sigma Chemical Co.), 0.1% NaN3). 
The  wells  were  washed  and  incubated  with  30  #1  of  0.4  #g/ml 
[t25I]fibronectin  for 2 h at 25°C. The wells were washed three times with 
Dulbecco's PBS and cut from the plate, and the bound radioactivity was 
counted. For some experiments, unlabeled fibronectin or a gelatin-binding 
fragment was used in place of the labeled protein. Binding was detected 
using monoclonal antibody 191 (Newman et al., 1987),  and t25I-goat anti- 
rat  IgG  (Kirkegaard and Perry  Laboratories,  Inc.,  Craithersburg,  MD). 
Competitive inhibition of fibroneetin binding to the immobilized peptides 
by soluble peptides or proteins was determined by including serial dilutions 
of the inhibitors to be tested and a  final concentration of 0.2  #g/m1  of 
[t25I]fibronectin. 
Binding of [t25I]fibronectin  to gelatin or type I  collagen were deter- 
mined using the ligands absorbed on polyvinyl chloride microtiter plates. 
To determine binding of fibronectin to thrombospondin, the unlabeled pro- 
tein (4 #g/well) was absorbed on Immulon-2 Removawells by incubation for 
3 h at 37°C. The wells were emptied and incubated with PBS-1% BSA buffer 
for 30 min. Binding of labeled fibronectin and inhibition were determined 
as described above except that the incubation was for 2 h at 37°C in PBS- 
BSA buffer. 
Table L Fibronectin Binding to Immobilized Peptides 
Peptide/origin*  Sequence  FN Bound 
%* 
184 I'  SPWSEWTSCSTS  0.3 
185 F  SHWSPWSSCSVT  0.2 
186 13  GPWSPWD I CSVT  0.3 
245 13  VTCGGGVQKRSRL  0.2 
246 12  KRFKQDGGWSHWSPWSS  12.2 
256 12  GGWSHWSPWSS  5.6 
259 A  GGWSHASPWSS  0.4 
263 F  KRFKQDGGWSHWSP  5.7 
266 A  KRFKQDGGASHASP  0.1 
292  I  s  WSHWSP  1.1 
300 I s  GGWSHW  51.0 
322  F  QDGGWS  0.2 
317 I I  DGWSPW  0.2 
318  13  GGWGPW  0.3 
319 A  GTWSEW  0.3 
320 A  GFWSEW  0.3 
297 C-term  THYRWRLSHRPKTGF I RV  0.2 
* The synthetic peptides were derived from the first (I1), second (I2), or third type I repeat of thrombospondin (I  3) or from the carboxyl-terminal  globular domain 
(C-term).  Peptides labeled A are analogs  of the thrombospondin sequences with amino acid substitutions  as indicated. 
* Fibronectin binding to the immobilized  peptides was determined using microtiter plate wells coated with 100 #g/ml of each peptide. 
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to Immobilized  Peptide  GGWSHW 
Peptide  Sequence  IC50 
300  GGWSHW  29 ±  11 
338  GGWTHW  150 
339  GGWAHW  280 
333  GGWSKW  >300 
334  GGYSHW  >300 
335  GGWSHY  >300 
340  AAWSHW  >300 
341  DGWSHW  >300 
342  GWSHW  >300 
322  QDGGWS  >300 
292  WSHWSP  >300 
246  KRFKQDGGWSHWSPWSS  =200 
256  GGWSHWSPWSS  >300 
259  GGWSHAS PWSS  >300 
* Concentrations of peptide required for 50 % inhibition of fibronectin binding 
to immobilized peptide GGWSHW. 
For determination of the pH-dependence for inhibition of flbronectin 
binding to gelatin, a series of buffers of constant ionic strength, 0.15, were 
prepared (McKerlzie,  1978)  containing 1% BSA and used in place of the 
PBS-BSA buffer.  Tris-HCl,  Tris-citrate,  sodium phosphate, and  sodium 
acetate buffers were used. 
Adhesion Assays 
Human breast carcinoma cell line MDA-MB-435s (American Type Culture 
Collection, Rockville, MD) and human melanoma cell line A2058 (Todaro 
et al.,  1980) were maintained in monolayer culture at 37°C with 5% CO2 
in Roswell Park  Memorial Institute 1640 medium containing 10%  FBS. 
Subconfluent cells were trypsinized and resuspended in RPMI  1640 me- 
dium containing 0.1%  BSA. Gelatin or fibronectin were coated on plastic 
disks in 24 well plates and incubated for 2 h at 37°C. After the supernatant 
was removed, the disks were blocked with 1% BSA-Tris buffer, pH 7.8 for 
30 rain at room temperature. The disks were washed twice with PBS, and 
0.4 ml of RPMI 1640 medium containing 0.1% BSA (and 2/~g/ml fibronec- 
tin for wells containing gelatin-coated disks) and the indicated concentra- 
tions of inhibitory peptides were added to the wells. A  suspension of 105 
cells in 0.1 ml was added to the wells and incubated at 37°C with 5% CO2 
for 1 h. The disks were washed to remove nonadherent cells and stained. 
Adherent cells were counted microscopically. 
Results 
Several synthetic peptides containing portions of the type I 
repeat sequences of human thrombospondin-1  were tested 
for binding to fibronectin in a solid phase assay (Fig. 1 and 
Table I). Of the larger peptides tested from the three type I 
repeats or the carboxyl terminal domain of thrombospondin, 
only peptide 246  (KRFKQDGGWSHWSPWSS) bound la- 
beled fibronectin. Binding did not require the amino termi- 
nal basic residues of peptide 246, based on the activity of the 
peptide 256 (GGWSHWSPWSS). At least two Trp residues 
were required, based on the activity of peptide 263  (KRF- 
KQD~SHWSP)  but not of peptide 266 (KRFKQDGGA- 
SHASP). The central Trp residue in peptide 256 is required 
for activity, since the peptide GGWSHASPWSS was inac- 
tive (Table  I).  Among the  series  of overlapping peptides 
QDGGWS, GGWSHW, WSHWSP,  and SHWSPWSS, only 
GGWSHW was strongly active (Table I). At saturating con- 
centrations of this peptide, 100/~g/ml, more than 50% of the 
added fibronectin was bound to the latter peptide (Fig.  1). 
The  active  peptide  is  from  the  second  type I  repeat  of 
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Figure 1. Binding of fibronectin to immobilized thrombospondin 
peptides. The indicated concentrations  of  the peptides SHWSPWSS 
(e),  KRFKQDGGWSHWSPWSS (o),  KRFKQDGGWSHWSP 
(A), GGWSHW  (zx), or GGWSHWSP  (l) were adsorbed on poly- 
vinyl cMoride  microtiter plate wells by incubation for 3 h at 25°C. 
Binding of 0.5 #g/ml [=zsI]fibronectin  to the adsorbed peptides was 
determined at 25°C as described in Materials and Methods. 
thrombospondin-1. Synthetic peptides derived from the cor- 
responding positions in the first and third type I  repeats, 
DGWCSPW and GGWGPW,  were inactive (Table I). 
Because direct binding to immobilized peptides is influ- 
enced both by the efficiency of peptide adsorption on plastic 
and potential changes in conformation induced by this ad- 
sorption,  the specificity of fibronectin binding to peptide 
GGWSHW was further examined by inhibition assays (Fig. 
2  and  Table  II).  Binding  of fibronectin  to  immobilized 
GGWSHW was inhibited by soluble GGWSHW, with 50% 
inhibition at 29 tiM. Three hexapeptides containing conser- 
vative  single amino  acid  substitutions,  GGWSKW,  GGY- 
SHW, or GGWSHY were inactive. Thus, the two Trp resi- 
dues and the His residue are essential. The Ser residue is 
optimal for binding but not absolutely required (Fig. 2). Sub- 
stitution with a  Thr residue decreased activity ~five-fold. 
Substitution with an Ala residue also produced an active pep- 
tide, with a slightly higher inhibition constant than the Thr 
analog. The presence of two Gly residues strongly enhanced 
activity relative to the analog with one Gly residue. Substitu- 
tion of both Gly residues with Ala or of the first Gly residue 
with Asp abolished activity. As was found in direct binding, 
the corresponding hexapeptides from the first and third re- 
peats of thrombospondin were inactive. Peptide 246 was a 
weak inhibitor, but other peptides that were weakly active in 
the direct binding assay did not inhibit fibronectin binding 
to immobilized GGWSHW. 
Peptides containing the sequence Trp-Ser-Xaa-Trp  were 
shown previously to bind to heparin and inhibit interactions 
of several proteins with sulfated glycoconjugates (Guo et al., 
1992a,b).  To examine the relationship between fibronectin 
and heparin-binding activities, several  of the peptides were 
tested as inhibitors of thrombospondin binding to heparin. 
The active peptide GGWSHW and the inactive analog GGW- 
SKW were both weak inhibitors of binding to heparin (IC50 
=  100/~M), whereas the peptides GGYSHW and GGWSHY 
were inactive (ICs0 >  400/zM).  The peptides GTWSEW 
and GFWSEW, which were inactive for binding fibronectin 
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Figure 2. Specificity of inhibition of fibronectin binding to throm- 
bospondin peptide GGWSHW by synthetic peptides. Binding of 
['25I]fibronecdn (0.5/~g/ml) to microtiter plate wells coated with 
50/~g/ml of GGWSHW was determined in the presence of the indi- 
cated concentrations of the peptides in solution: GGWSHW, e; 
GGWTHW, o; ~AHW,  m; GWSHW, n; AAWSI-lW, v; and 
DGWSHW, ~. Results are mean  +  SD for duplicate determina- 
tions and arc presented as percent of specific binding determined 
in the absence of inhibitor. 
(Table I), were good inhibitors of thrombospondin binding 
to heparin with IC~0 values of 40 and 50 #M, respectively. 
Thus, the fibronectin and heparin binding activities are dis- 
tinct. 
Both unlabeled fibronectin and thrombospondin competed 
for binding  of[~25I]fibronectin to  the  peptide GGWSHW 
(Fig.  3), but several irrelevant proteins tested (ovalbumin, 
transferrin, fetuin, goat IgG, and routine laminin) did not 
(ICs0 >  200 #g/ml,  Fig. 4  and results not shown).  Inhibi- 
tion by thrombospondin suggested that the peptide binds to 
fibronectin at a  site involved in binding  of fibronectin to 
thrombospondin.  An  alternative  explanation  for  the  ob- 
served inhibition, that thrombospondin competes by binding 
to peptide ~SHW,  could not be excluded, because la- 
beled thrombospondin bound to the immobilized peptide, al- 
beit much weaker than fibronectin (results not shown). 
To further define the sites involved in the interaction of 
fibron~ti  n with this peptide and with intact thrombospon- 
din, proteolytic fragments of fibronectin were tested as in- 
hibitors.  Of the proteolytic fragments tested,  the gelatin- 
binding domain was  the best inhibitor of [t25I]fibronectin 
binding to immobilized peptide GGWSHW (Fig. 4). Proteo- 
lytic fragments  containing the  cell binding  domain were 
~,d0-fold weaker, and fragments containing the fibrin-binding 
I or carboxyl-terminal heparin-binding domains of fibronec- 
tin were inactive. Of the recombinant fibronectin fragments 
tested, which contained portions of the fibrin I, cell-binding, 
and heparin-binding domains, only a 33-kD fragment from 
the cell binding domain was inhibitory. However, a 28-kD 
fragment containing all but the NH2 terminal 5-kD of the 
33-kD fragment was inactive and a 40-kD fragment with the 
same amino terminus as the 28-kD fragment was ,~10-fold 
less active. Because the sequence of the 33-kD recombinant 
fragment is contained in the 120-kD protcolytic fragment of 
fibronectin, and the latter fragment was a weak inhibitor, this 
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Figure 3. Inhibition of fibronectin binding to thrombospondin pep- 
tide GGWSI-IW  by soluble fibmnectin, thrombospondin, or peptide 
~SHW.  Binding of [~25I]fibmnectin (0.5/~g/ml) to microtiter 
plate wefts coated with 50/zg/ml of GGWSHW was determined in 
the  presence  of  the  indicated  concentrations  of  the  peptide 
GGWSHW (e), fibronectin (A), or thrombospondin (,,). 
may represent a  secondary binding  site that requires the 
amino terminal sequence of the 33-kD fragment or is present 
but cryptic in the 28-kD recombinant fragment. Its activity, 
however, is less than that of the gelatin binding fragments. 
Inhibition by these fragments was not due to binding to the 
labeled ligand,  as none of the fragments used bound sig- 
nificantly to fibronectin in a direct binding assay (results not 
shown). Iodinated gelatin-binding fragment did not bind to 
the  peptide  GGWSHW.  However,  direct  binding  of the 
gelatin-binding domain to peptide GGWSHW was confirmed 
using a monoclonal antibody that recognized this domain as 
a detection reagent (Fig. 5). Antibody 191 was chosen be- 
cause it bound to the gelatin-binding domain of fibronectin 
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Figure 4. The gelatin-binding domain of fibronectin mediates bind- 
ing of fibronectin to the thrombospondin peptide GGWSHW. Bind- 
ing of [t25I]fibronectin  (0.5/~g/ml) to microtiter plate wells coated 
with 50 #g/ml of GGWSHW was determined in the presence of  the 
indicated concentrations of  proteolytic fragments of fibronectin: in- 
tact fibronectin (e),  30-kD gelatin-binding domain (o), 33-kD 
recombinant cell  binding  domain  (A), 28-kD  recombinant cell 
binding domain (A), transf~rrin (x7), 31-kD fiibrin-binding  domain 
(m), 40-kD heparin-binding domain (o), or 120-kD ceft-binding 
domain (v). 
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intact  fibronectin to  the  peptide  GGWSI-IW  (results  not 
shown). Using this antibody for detection, binding of both 
intact  fibronectin and the  gelatin-binding fragment were 
saturable, with half saturation obtained at 0.7 and 15/~g/ml, 
respectively. No binding was detected using the control frag- 
ment from the cell-binding domain of fibronectin. 
The  gelatin-binding fragment also inhibited fibronectin 
binding to intact thrombospondin (Fig. 6), indicating that the 
same domain of fibronectin binds to both the thrombospon- 
din peptide and to intact thrombospondin. Binding of  throm- 
bospondin to fibronectin was partially inhibited by peptide 
300 (Fig. 6), but the degree of inhibition was variable be- 
tween experiments and incomplete. The fibrin-binding do- 
main of fibronectin also binds to thrombospondin (Homand- 
berg  and Kramer-Bjerke,  1987)  and may partially mask 
effects of the peptide on the interaction of thrombospondin 
with the gelatin-binding domain of fibronectin. 
The peptide GGWSI-IW also inhibited binding of fibronec- 
tin to gelatin (Fig. 7). The inhibition was specific in that the 
related  peptides,  GGWSKW,  GGYSI-IW, and  GGWSHY, 
with  single amino acid substitutions from the  active se- 
quence were inactive. Comparable specificity of inhibition 
was obtained using immobilized native type I  collagen in 
place of gelatin. The peptide GGWSHW inhibited fibronec- 
tin binding to type I collagen with IC~o =  40/zM.  GGW- 
AHW was a weak inhibitor, whereas WSHWSP, GG~SKW, 
GGYSHW,  GGSVSHY, AAWSI-IW, DGWSHW,  and GGW- 
THW were inactive. 
Inhibition of fibronectin binding to gelatin by the peptide 
GGWSHW was pH dependent (Fig. 8). Inhibition was not 
detectable at pH 8.5. The potency increased with decreasing 
pH to a maximum ICs0 of 1/zM at pH 4.5 to 5.5. At pH 4.0, 
an inhibition constant could not be determined as fibronectin 
did not bind to immobilized gelatin. Direct binding of fibro- 
nectin to  the peptide  showed a  complex pH-dependence 
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Figure 5. Direct binding of the fibroneefin gelatin-binding  domain 
to peptide GGWSHW. Microtiter plate wells coated using 50/=g/m] 
peptide GG'WSHW  and blocked by incubation with I% BSA were 
incubated with the indicated concentrations of the 30-kD proteo- 
lytic gelatin-binding  domain of fibronectin (o), the 120-kD proteo- 
lytic cell binding fragment (A), or intact fibronectin  (e). The wells 
were washed and incubated sequentially  with 5/~g/m] antibody 191 
and 12~I-goat anti-mouse IgG. Bound radioactivity is presented as 
mean 5- SD for duplicate determinations. 
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Figure  6, Gelatin  binding  domain of  fibronectin  inhibits  fibmnectin 
binding to thrombospondin. Microtiter  plate  wells  were coated 
with  4 #g  of  thrombospondin in  50  td  of  Dulbeccds  PBS by  incubat- 
ing for 3 h at 25*(2.  The wells  were emptied and incubated  with 
Dulbecco's PBS containing  I% BSA for  30 rain.  The wells  were 
emptied and incubated  with  0.5 #g/ml [~2Sl]fibmnectin  in  the  pres- 
ence of  the indicated  concentrations  of  30-kD proteolytic  gelatin- 
binding  fragment (e),  intact  fibronectin  (o),  or GGWSI-IW (=). 
(data not shown). Binding was strong at pH values less than 
6 and from 7.5 to 8 but weaker at pH 6.5 to 7. 
The fibronectin-binding peptide GGWSHW was tested for 
functional effects on the adhesion of  human breast carcinoma 
and melanoma cell lines. The peptide GGWSHW inhibited 
fibronectin-dependent adhesion of A2058  melanoma cells 
(Fig. 9 A) or MDA MB435s breast carcinoma cells (Fig. 10 
A) to immobilized gelatin. At the concentrations used, the 
cells adhered weakly to gelatin in the absence of added fi- 
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Figure 7. Peptide GGWSHW  specifically  inhibits fibronectin bind- 
ing to gelatin. Wells of a polyvinyl chloride microtiter plate were 
incubated for 3 h at 25"C with 2/~g/ml  of  gelatin in Dulbecco's  PBS. 
The wells were emptied and incubated with Dulbeeco's PBS con- 
taining 1% BSA for 30 rain. The wells were emptied and incubated 
with 0.5/~g/ml [~ZSl]fibronectin  in the presence of the indicated 
concentrations of peptide GGWSHW (e), GGWSKW (o), GGY- 
SHW (A), or ~-'WSHY ('9  for 2 h at 25"C. The wells were 
washed four times with PBS, cut from the plate and the bound ra- 
dioactivity was counted. 
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Figure  8. pH-dependence for inhibition by peptide GGWSHW of 
fibronectin binding to gelatin. Inhibition was determined as in Fig. 
7 using a series of  buffers of  constant ionic strength, 0.15. Error bars 
indicate +SD for determinations of dose for 50% inhibition (IC5o) 
in two or more buffer systems. 
bronectin.  The  stimulated  adhesion  in  the  presence  of 
fibroneetin was inhibited in a dose-dependent manner by the 
peptide GGWSHW. The inhibition was specific in that two 
homologous peptides that lacked fibronectin binding activ- 
ity, GGWSKW and WSHWSP, were inactive. Direct adhe- 
sion of A2058 cells (Fig. 9 B) or MDA 435s cells (Fig.  10 
B) to immobilized fibronectin was not inhibited by the pep- 
tide GGWSHW or the control peptides, but adhesion of the 
breast carcinoma ceils to fibronectin was inhibited by the 
peptide GRGDS (Fig. 10 B). Therefore, interaction of fibro- 
nectin with integrin receptors on the breast carcinoma cells 
is not inhibited by the peptide GGWSHW. 
Fibronectin-mediated adhesion  of the  breast  carcinoma 
cells to native type I collagen was also inhibited by the pep- 
tides  GGWSHW  and  GRGDS  but  not  by  GGWSKW  or 
WSHWSP (Fig.  11). Direct adhesion to type I collagen was 
stronger than to gelatin. However, the effects of the peptide 
GGWSHW were specific for fibronectin stimulated  adhe- 
sion, as direct adhesion to type I collagen was not inhibited 
by GGWSHW (results not shown). 
Discussion 
Fibronectin is an important extracellular matrix component 
that mediates cell interactions and extracellular matrix as- 
sembly during normal development. It also participates in 
hemostasis  and  wound  healing,  and  peptides  that  inhibit 
fibronectin interactions with cells have been demonstrated to 
inhibit tumor metastasis  in animal models (Humphries et 
al.,  1986). Several synthetic peptides from fibronectin have 
been shown to inhibit interactions of fibronectin with cell 
surface integrin receptors (reviewed in Yamada,  1991). Re- 
cently, a  synthetic peptide from the first type III repeat of 
fibronectin was demonstrated to inhibit binding of fibronec- 
tin to itself during matrix assembly (Morla and Ruoslahti, 
1992). The peptides described in the present work define a 
new class of inhibitors of fibronectin function. The peptide 
GGWSHW binds specifically to fibronectin. It inhibits inter- 
actions of fibronectin with collagen but not with cell surface 
Figure  9.  Peptide GGWSHW inhibits fibronectin-dependent cell 
adhesion to denatured collagen. (A) Adhesion of human melanoma 
cells, A2058, was determined to plastic coated with 1/~g/ml  gelatin 
in the presence or absence of 1 #g/well of soluble fibronectin and 
with fibronectin in the presence of the indicated concentrations of 
the peptide GGWSHW (solid bars) or the control peptides GGW- 
SKW (grey bars) and WSHWSP (striped bars). (B) Direct adhesion 
of A2058 melanoma cells to plastic coated with I0 ~g/ml fibronec- 
tin was determined as in A. Data are presented as a percent of con- 
trol adhesion determined in the absence of peptides (mean +  SD, 
n  =  6). 
integrin receptors for fibronectin. Therefore, this class of 
peptides  may have  multiple  applications  in  regulation  of 
fibronectin-dependent cell-matrix  interactions  involved in 
tumorigenesis,  metastasis,  wound repair,  and hemostasis. 
The peptide GGWSHW inhibits fibronectin-mediated adhe- 
sion of cells to a collagen matrix. We are currently examin- 
ing the ability of the peptides to inhibit other biological ac- 
tivities of fibronectin in normal and transformed cells. 
Interaction of the peptide GGWSHW with fibronectin is 
specific by several criteria. First, high affinity binding to the 
immobilized peptide was obtained only with fibronectin, and 
several unrelated extracellular proteins failed to compete for 
fibronectin binding to the immobilized peptides.  Based on 
activities of fibronectin fragments, the gelatin-binding do- 
main is the major site for binding to the peptide. A secondary 
site, however, may also be present in the cell binding do- 
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Fibronectin mediated adhesion to gelatin (A) or direct adhesion to 
fibronectin (B) were determined as in Fig. 8. Inhibition by peptides 
GGWSHW (solid bars), GGWSKW  (grey bars), WSHWSP (striped 
bars), or GRGDS (hatched bars) is presented as a percent of  control 
(mean  +  SD, n  =  6). 
main. Second, binding is highly sequence specific. The two 
Trp residues and the His residue are essential, and changing 
any of the other residues in the hexapeptide substantially 
decreases its activity. Based on the pH-dependence for in- 
hibiting  fibronectin binding to gelatin,  protonation of the 
histidine may be required for this activity but probably is not 
required for direct binding of the peptide to fibronectin. Fi- 
nally,  the  specificity for binding  to fibronectin is  distinct 
from that  for binding of peptides containing the Trp-Ser- 
Xaa-Trp  consensus  sequence  to  heparin.  GGWSHW  has 
weak heparin binding activity, whereas the peptide KRF- 
KQDGGWSHWSPWSS binds strongly to heparin (Guo et 
al.,  1992a,b). The order of activities is reversed for binding 
of these  two peptides to fibronectin.  The peptides GGW- 
SKW, GTWSEW, and GFWSEW have equivalent or better 
Figure IL Fibronectin-mediated adhesion of breast carcinoma cells 
to native type I collagen is inhibited by GGWSHW. Cell attachment 
was determined to immobilized type I collagen (striped bar) or to 
type I collagen mediated by soluble fibronectin, alone (grey bar) 
or  in  the  presence  of the  indicated  concentrations  of peptide 
~SHW  (e), ~SKW  (o), WSHWSP (,), or GRGDS (zx), 
mean  +  SD, n  =  6. 
heparin-binding activities than GGWSHW but are inactive 
for inhibiting binding of fibronectin to the immobilized pep- 
tide GGWSHW or to gelatin. 
The peptide identified here is probably not the only site 
for interaction of thrombospondin with fibronectin, and at 
least two domains of thrombospondin have been shown to 
bind to fibronectin (Dardik and Lahav,  1989).  Proteolytic 
fragments from the amino terminus and the 70-kD core of 
thrombospondin both bound to intact fibronectin. Binding to 
thrombospondin may also be mediated by more than one site 
on fibronectin.  There is  direct evidence for a  role of the 
fibrin-binding domain of fibronectin in its interaction with 
thrombospondin (Homandberg and Kramer-Bjerke, 1987). 
However, Gelder and  Brown  (1987)  reported that  throm- 
bospondin can inhibit interactions of fibronectin with gela- 
tin. Both whole thrombospondin isolated from platelets and 
an unidentified component of human plasma inhibited agglu- 
tination of mixtures of gelatin-coated latex beads and fibro- 
nectin-coated beads. The domains or amino acid sequences 
responsible for this activity were not examined. The present 
results,  that  the gelatin-binding domain of fibronectin in- 
hibits binding of fibronectin to both thrombospondin and the 
thrombospondin peptide GGWSHW and  that  this  peptide 
specifically inhibits thrombospondin binding to fibronectin, 
are consistent with the latter data. 
The ability of a  sequence in thrombospondin to inhibit 
fibronectin mediated cell adhesion to a collagen matrix sug- 
gests a mechanism for the anti-adhesive activity of throm- 
bospondin (reviewed in Sage and Bornstein, 1991). Throm- 
bospondin disrupts  focal contact adhesions of endothelial 
cells attached to a fibronectin matrix (Murphy-Ullrich and 
Hbbk,  1989). The mechanism of this effect is unknown, but 
inhibition of  the activity of thrombospondin by sulfated poly- 
saccharides indicated that a heparin-binding domain of throm- 
bospondin  was  involved.  However,  both  fibronectin  and 
heparin inhibited the binding to endothelial cells of intact 
thrombospondin or the 70-kD fragment (Dardik and Lahav, 
1991),  suggesting that the heparin and fibronectin binding 
sites in the 70-kD fragment are proximal.  These data are 
consistent with the binding  activities of isolated peptides 
from the type I  repeats of thrombospondin in that the fi- 
bronectin binding  sequence is  contained within a  peptide 
that binds with high affinity to heparin. We have previously 
shown that each of the three type I repeats of thrombospon- 
din contain heparin-binding sequences with the consensus 
sequence Trp-Ser-Xaa-Trp-Ser (Guo et al.,  1992a,b).  The 
present  results  identify  the  fibronectin-binding  sequence 
Gly-Gly-Trp-Ser-His-Trp, which occurs only in the second 
Type I repeat. The first Trp residue in the Trp-Ser-Pro-Trp- 
Ser sequence from this repeat corresponds to the carboxyl- 
terminal Trp residue in the fibronectin binding sequence. 
Because  the  thrombospondin  peptide  ~SHW  is  anti- 
adhesive for fibronectin mediated cell adhesion to gelatin or 
type II collagen, the sequence could account for some of the 
inhibitory effects of thrombospondin on cell adhesion. The 
overlap with the heparin binding sequence would account for 
sensitivity of the anti-adhesive activity to heparin (Murphy- 
Ullrich and Hffk,  1989). 
The availability of this sequence in the intact protein and 
in  the  presence of heparin,  however,  remains  to  be  ad- 
dressed. Because the hexapeptide ~SHW  bound fibro- 
nectin better than the larger peptides containing the same se- 
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to be partially cryptic in thrombospondin. The lower activity 
of peptide 246 relative to ~SHW  suggests that neighbor- 
ing residues in the larger peptide could directly inhibit bind- 
ing of the active sequence to fibronectin. Further studies will 
be required, however, to examine effects of neighboring se- 
quences on the conformation of the active sequence in this 
family of peptides and to determine the accessibility and 
conformation of this sequence in native thrombospondin. 
Previous studies suggested that the fibronectin binding site 
in the 70-kD fragment of endothelial cell thrombospondin is 
cryptic in the presence of  divalent cations (Dardik and Lahav, 
1989). However, the ability of antisera to synthetic peptides 
from the type I repeats of thrombospondin to bind to intact 
thrombospondin demonstrates that at least portions of the 
type I repeats are accessible in the native protein (Prater et 
al., 1991; Tuszynski et al., 1992). The amino-terminal fibrin- 
binding domain of fibronectin is a second site that mediates 
binding to thrombospondin. Therefore, it may be difficult to 
efficiently inhibit binding of the intact proteins using only an 
inhibitor of interaction with the gelatin-binding domain. 
The high degree of conservation of the fibronectin-binding 
hexapeptide in the thrombospondin gene family suggests  a 
functional role of this sequence (Table liD.  The sequence 
Gly-Gly-Trp-Ser-His-Trp  is completely conserved in the sec- 
ond type I repeats of mouse and human thrombospondin-1 
and in thrombospondin-2 from mouse and chicken (Laherty 
et al., 1992). However, it is not present in any of the six type 
I repeats in the neuronal homolog of  thrombospondin, F-spon- 
din (Klar et al.,  1992).  The heparin-binding consensus se- 
quence  Trp-Ser-Xaa-Trp-Ser  is  conserved  in  complement 
components and in many members of the cytokine receptor 
and  transforming growth  factor  /3  superfamilies  (Bazan, 
1990;  Wharton, 1991; Guo et al.,  1992a,b).  The sequence 
Gly-Gly-Trp-Ser-His-Trp,  however,  does not occur in these 
proteins.  A  search of the Swiss-Prot data base using the 
search  sequence  Gly-Gly-Trp-Ser-His-Trp  yielded  several 
other proteins with similar sequences (Table HI). Epstein- 
Barr virus ribonucleotide reductase contains the most ho- 
mologous sequence, Gly-Gly-Trp-Phe-His-Trp,  and the flank- 
ing sequences contain three additional matches with the se- 
quence of  the second thrombospondin type I repeat, including 
Table IlL Amino Acid Sequence  Homologies  with the 
Fibronectin-binding  Sequence from Thombospondin 
Source  Sequence 
Human THBS1 
mouse Thbsl 
mouse Thbs2 
chicken Thbs 2 
EBV ribonucleotide reductase 
chicken AchR~x 
T. california AchRt~ 
rat AchRt~ 
mouse AchRtx 
bovine AchRtx 
KRFKQDGGWSHWSPWSSC 
KRFKQDGGWSHWSPWSSC 
TRIRQNGGWSHWSPWSSC 
HRIRQDGGWSHWSPWSSC 
~KQSKYA~WFHWHDWAGC 
WVMKDYRGWKHWVYYACC 
WVMKDYRGWKHWVYYTCC 
WVIKEARGWKHWVFYSCC 
WVIKEARGWKHWVFYSCC 
WVIKESRGWKHWVFYACC 
0  0  ~  ~ 
Sequence identity with the thrombospondin sequence is indicated by bold resi- 
dues. Residues in acetyleholine receptor ct subunit (AehRot) identified by cross- 
linking to receptor ligands (Karlin,  1991) are indicated by *. Residues impli- 
cated in ot-bungarotoxin binding (Barehan et al.,  1992) are indicated by O. 
the third Trp residue and the basic residues involved in hepa- 
rin binding. This match may be fortuitous, however, as this 
homologous sequence is not conserved in other viral or eu- 
karyotic ribonucleotide reductase genes (Nikas et al., 1986). 
A potentially  more interesting homology is with the sequence 
Gly-Trp-Lys-His-Trp in the ot-subunit of the nicotinic acetyl- 
choline receptor, which is highly conserved among all verte- 
brate acetylcholine receptor sequences. Based on affinity la- 
beling, a  peptide containing this sequence plays a  role in 
acetylcholine binding to the receptor. Three residues adja- 
cent to the homologous sequence, Tyr 190, Cys 192 and Cys 
193, have been implicated in binding acetylcholine analogs 
(reviewed in Karlin,  1991). The latter Cys residue is con- 
served at the same relative position in the thrombospondin 
genes. Recombinant active site fragments from the acetyl- 
choline receptor containing the homologous sequence bind 
ct-neurotoxins with relatively high affinity (Ohana and Ger- 
shoni, 1990). The second Trp residue, Trp 187, may partici- 
pate in binding of ot-bungarotoxin  to the receptor (Barchan 
et al.,  1992). 
Site directed mutagenesis of two cytokine receptors also 
identified  the WSXW motif  as a potential "binding" sequence 
(Miyazaki et al., 1991; Yoshimura et al., 1992). The ligands 
that interact with this site were not identified, but loss of 
receptor processing or activity after mutation of the WSXW 
consensus suggests that cellular factors involved in protein 
folding, intracellular processing, or signal transduction are 
potential ligands. Using synthetic peptides, we have identi- 
fied two ligands for this sequence: heparin and related sul- 
fated glycoconjugates  for WSXW and fibronectin for the sub- 
set with X =  His. We propose that there may be other ligands 
yet to be identified for other subsets of this consensus se- 
quence. 
The type I and type II repeats from the collagen-binding 
domain of fibronectin have been conserved in several other 
proteins (Peterson et al.,  1989).  If the sequence or confor- 
mational  epitope  responsible  for  binding  of the  peptide 
GGWSHW to fibronectin is conserved in these proteins, the 
thrombospondin peptide may be a useful inhibitor of their 
functions. The thrombospondin peptides are therefore being 
tested as inhibitors of  the activities of other proteins that con- 
tain domains homologous to the fibronectin gelatin-binding 
domain. Preliminary experiments indicate that the peptide 
GGWSHW inhibits gelatinase activity seqreted by corneal 
endothelial cells (J.  M.  Sipes,  H.  C. Krutzsch, and D.  D. 
Roberts, unpublished results). 
We  thank  Dr.  Steven Akiyama  for providing  antibody to  the  gelatin- 
binding domain and Biotechnology General,  Ltd.  (Rehovot, Israel) for 
providing recombinant fragments of fibronectin and Dr. Henry Fales for 
mass spectrometry of the synthetic peptides. 
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